MENLO PARK, Calif., Oct. 13, 2016 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ: DERM ), a biopharmaceutical company dedicated to identifying, developing and commercializing innovative, differentiated therapies to improve the lives of patients with dermatologic diseases, today announced that data from its DRM01 and DRM04 clinical programs will be presented at the 35 th Anniversary Fall Clinical Dermatology Conference being held in Las Vegas Oct. 20 – 23, 2016.
Updated data regarding dose efficacy from the Phase 2b trial evaluating DRM01 as a potential option for patients with acne vulgaris will be presented. The results from two Phase 3 clinical trials evaluating DRM04 as a potential treatment for patients with primary axillary hyperhidrosis (excessive underarm sweating) will also be highlighted during the meeting.
“Fall Clinical is an important meeting that allows leading dermatology practitioners the opportunity to discuss the latest advancements in the specialty,” said Eugene A. Bauer, M.D., chief medical officer of Dermira and a dermatologist. “We are pleased to have an opportunity to provide this community with an update on the progress of Dermira’s two late-stage clinical development programs.”
Presentations of Interest:
Title: DRM01 for the treatment of acne vulgaris: Primary results from the DRM01-ACN02 Phase 2b randomized controlled trial Date and Time: Available for the duration of the meeting Presenter: Jim Del Rosso, D.O., an adjunct clinical professor of dermatology at Touro University College of Osteopathic Medicine Session: General Session
Title: DRM04 for the treatment of axillary hyperhidrosis: Primary results from the ATMOS-1 and ATMOS-2 Phase 3 randomized controlled trials Date and Time: Available for the duration of the meeting Presenter: David Pariser, M.D., professor at Eastern Virginia Medical School’s Department of Dermatology Session: General Session
About Dermira Dermira is a biopharmaceutical company dedicated to identifying, developing and commercializing innovative, differentiated therapies to improve the lives of patients with dermatologic diseases. Dermira’s portfolio includes three late-stage product candidates that target significant unmet needs and market opportunities: CIMZIA® (certolizumab pegol), in Phase 3 development in collaboration with UCB Pharma S.A. for the treatment of moderate-to-severe chronic plaque psoriasis; DRM04, in Phase 3 development for the treatment of primary axillary hyperhidrosis (excessive underarm sweating); and DRM01, in Phase 2b development for the treatment of facial acne vulgaris. Dermira is headquartered in Menlo Park, California. For more information, please visit www.dermira.com .
In addition to filings with the Securities and Exchange Commission (SEC), press releases, public conference calls and webcasts, Dermira uses its website (www.dermira.com) and LinkedIn page (https://www.linkedin.com/company/dermira-inc-) as channels of distribution of information about its company, product candidates, planned financial and other announcements, attendance at upcoming investor and industry conferences and other matters. Such information may be deemed material information and Dermira may use these channels to comply with its disclosure obligations under Regulation FD. Therefore, investors should monitor Dermira’s website and LinkedIn page in addition to following its SEC filings, press releases, public conference calls and webcasts.
Forward-Looking Statements The information in this press release contains forward-looking statements and information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are subject to the “safe harbor” created by those sections. This press release contains forward-looking statements that involve substantial risks and uncertainties, including statements with respect to the potential use of DRM01 as a treatment option for patients with acne vulgaris and the potential use of DRM04 as a treatment option for patients with primary axillary hyperhidrosis. These statements deal with future events and involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. Factors that could cause actual results to differ materially include risks and uncertainties such as those relating to the design, implementation and outcome of Dermira’s clinical trials; Dermira’s dependence on third-party clinical research organizations, manufacturers and suppliers; Dermira’s ability to obtain regulatory approval for its product candidates; and Dermira’s ability to continue to stay in compliance with applicable laws and regulations. You should refer to the section entitled “Risk Factors” set forth in Dermira’s Annual Report on Form 10-K, Dermira’s Quarterly Reports on Form 10-Q and other filings Dermira makes with the SEC from time to time for a discussion of important factors that may cause actual results to differ materially from those expressed or implied by Dermira’s forward-looking statements. Furthermore, such forward-looking statements speak only as of the date of this press release. Dermira undertakes no obligation to publicly update any forward-looking statements or reasons why actual results might differ, whether as a result of new information, future events or otherwise, except as required by law.
Contacts: Media: Erica Jefferson Senior Director, Head of Corporate Communications 650-421-7216 erica.jefferson@dermira.com Investors: Andrew Guggenhime Chief Operating Officer and Chief Financial Officer 650-421-7200 investors@dermira.com Robert H. Uhl Westwicke Partners Managing Director 858-356-5932 robert.uhl@westwicke.com
